2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Bioinformatics, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Bispecific Antibody Therapy, Immunotherapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Study Population, Human, Adult, Pediatric, Animal Model
PAPER

1472 Pharmacological characterization of AZD3632, a menin-KMT2A inhibitor, as targeted treatment for KMT2A-altered and NPM1-mutant acute leukemia

Pearl Lee, Justine Roderick-Richardson2, Maaike Emmelot-van Hoek3, Bart van Lith4, Roos Meering5, Keith Dillman6, Michael Silkes7, Sofia Ferreira8, Luuk Janssen9, Claudia Sacchetto, PhD10, Neeraj Aryal, PhD11, Siyu Liu, PhD12, Gerjan de Bruin, PhD13, Kevin Beaumont14, Ken Wood15, Alwin Schuller, PhD16, Lisa Drew, PhD17
1 AstraZeneca, Oss, Netherlands
2 AstraZeneca, Waltham, Massachusetts, United States
3 AstraZeneca, Oss, Netherlands
4 AstraZeneca, Oss, Netherlands
5 AstraZeneca, Oss, Netherlands
6 AstraZeneca, Waltham, Massachusetts, United States
7 AstraZeneca, Waltham, Massachusetts, United States
8 AstraZeneca, Cambridge, United Kingdom
9 AstraZeneca, Oss, Netherlands
10 AstraZeneca, Oss, Netherlands
11 AstraZeneca, Waltham, Massachusetts, United States
12 AstraZeneca, Waltham, Massachusetts, United States
13 AstraZeneca, Oss, Netherlands
14 AstraZeneca, Cambridge, United Kingdom
15 AstraZeneca, Waltham, Massachusetts, United States
16 AstraZeneca, Waltham, Massachusetts, United States
17 AstraZeneca, Waltham, Massachusetts, United States

KMT2A-rearranged (KMT2Ar, also known as MLLr) and NPM1-mutant (NPM1m) acute leukemias are driven by aberrant transcriptional programs characterized by dysregulated HOX gene expression and variable clinical outcomes. Because the menin–KMT2A interaction is a key regulator of this leukemogenic program, menin inhibition has emerged as a promising therapeutic strategy. Approved menin inhibitors (MIs), including revumenib and ziftomenib, have demonstrated meaningful CR/CRh rates in relapsed/refractory acute leukemia (30% (Issa et al., 2023) and 22% (Wang et al., 2025), respectively) and can produce durable responses. However, USPI-reported efficacy and safety data suggest there is room to improve both durability and tolerability. Dose-limiting toxicities and safety signals such as QT interval prolongation may restrict optimal dosing and target engagement, potentially allowing resistance to emerge. Among revumenib-treated patients, both responders and non-responders, 38.7% developed one or more MEN1 mutations (Perner et al., 2023), indicating that acquired resistance may arise through MEN1 alterations in a substantial subset of patients, alongside non-MEN1 mechanisms. These findings support the need for next-generation MIs with improved therapeutic indices capable of achieving deeper and more sustained target inhibition. AZD3632 was designed to address these limitations through optimized potency, selectivity, and drug-like properties intended to enable more complete menin inhibition at tolerable exposures.

Here, we report the discovery and comprehensive evaluation of the activity of AZD3632 as an orally bioavailable, highly potent and selective small molecule inhibitor of the menin-KMT2A interaction, now in Phase 1 clinical trials (MOMENTUM; NCT07155226).

AZD3632 demonstrated potent and selective preclinical activity consistent with menin inhibition. In a biochemical fluorescence polarization assay, AZD3632 disrupted the menin-KMT2A interaction, with mean IC50 values of 107 nM at 5 minutes and 43 nM at 180 minutes. In vitro assays demonstrated how AZD3632 selectively inhibited growth of KMT2Ar and NPM1-mutant (NPM1m) leukemia cell lines, with mean cell viability IC50 values of 38-81 nM, whereas KMT2A/NPM1 wild-type lines were insensitive (IC50 >10 µM). Mechanistically, AZD3632 suppressed canonical menin downstream genes, including MEIS1 and MEF2C, induced differentiation-associated markers including CD14, ITGAM, MNDA, and MPO, supporting on-target pathway modulation. In KMT2Ar cell-derived xenograft (CDX) models, AZD3632 monotherapy produced dose-dependent antitumor activity, with 97-99% tumor regression at 100-200 mg/kg twice daily, accompanied by marked downregulation of MEIS1 and MEF2C. Notably, at the highest dose tested, tumor suppression was maintained following treatment withdrawal. In disseminated KMT2Ar and NPM1m patient-derived xenograft (PDX) models, AZD3632 reduced peripheral blood leukemic burden by 71.8-99.4% and prolonged survival by 4 to >116 days versus vehicle, and was well tolerated across in vivo studies. AZD3632 combined with venetoclax or azacytidine showed combination benefit with increased cytotoxicity in MOLM-13 cells. In vivo, AZD3632 treatment with venetoclax+azacytidine or gilteritinib shows superior efficacy over monotherapy in MOLM-13 xenograft models with no tumor outgrowth in combination groups 12 weeks post-dosing.

We next assessed AZD3632 against clinically relevant MEN1 resistance mutations (T349M, M327I/V, S160T, G331D/R) associated with clinical resistance to other MIs. AZD3632 demonstrated a smaller drop-off in potency against mutant MEN1 cells compared to Revumenib, despite reduced potency relative to MEN1 WT cells. In agreement with these in vitro observations, AZD3632 showed dose-related antitumor activity against MOLM-13 tumors carrying the MEN1 M327I resistance mutation, with complete regressions observed at the highest dose tested. Additionally, combination studies in vivo showed AZD3632 combined with venetoclax/azacytidine or gilteritinib drove faster time to complete regressions than monotherapy at clinically relevant doses in MEN1 M327I MOLM-13 tumors.

Collectively, these data support the clinical evaluation of AZD3632 as a next generation MI designed to overcome the efficacy limitations of current agents. AZD3632 is being evaluated as monotherapy and in combination for acute leukemia patients harboring either KMT2A or NPM1 alterations (MOMENTUM; NCT07155226).

Pearl Lee: AstraZeneca - Current equity holder in publicly-traded company; AstraZeneca - Stock (publicly traded); AstraZeneca - Current Employment